NCT07085169 - Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions

Colo-rectal CancerThird-line and Beyond TherapyTAS 102Bevacizumab

Interventions

DRUG

Trifluridine/tipiracil (TAS-102) plus bevacizumab

Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This is a single-arm study with all patients receiving these two drugs.

Trial Locations (2)

Unknown

RECRUITING

SanMing First Hospital, Sanming

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER